Insperity (NSP) Q4 2025 earnings review
Margins Crushed by Claims, Aggressive Recovery Guided for 2026
Insperity's Q4 results confirmed the severity of its 2025 profitability crisis. While revenue grew a modest 3% YoY, Gross Profit collapsed 21% as healthcare claim costs spiraled out of control. The company swung to a Net Loss of $33M (vs. $9M loss in 24Q4). However, the narrative is entirely focused on a 'V-shaped' recovery in 2026. Management asserts that a new UnitedHealthcare contract and aggressive repricing will restore margins, guiding for FY26 Adjusted EPS to jump 64-164% YoY. The market must now weigh the demonstrated execution failure in 2025 against the structural fixes promised for 2026.
🐂 Bull Case
The new UnitedHealthcare contract (effective Jan 1, 2026) reduces the large claim pooling level to $500k. Combined with price hikes, this is expected to mechanically reset Gross Margins, driving the guided ~50-70% EBITDA growth in FY26.
The 'HRScale' joint solution with Workday is live. This opens a new TAM (Target Addressable Market) in the mid-market segment, potentially re-accelerating unit growth beyond the current anemic 1% rate.
🐻 Bear Case
Management consistently underestimated healthcare inflation throughout 2025 (pharmacy trends, utilization). If the 2026 'reset' assumptions are even slightly off, the aggressive profit guidance will be missed.
Insperity is passing significant costs to clients through pricing. While retention is currently reported as stable, the cumulative effect of price hikes in a softening labor market creates significant churn risk.
⚖️ Verdict: ⚪
Hold/Neutral. The Q4 financial damage was severe, but widely expected. The investment thesis now rests entirely on the execution of the 2026 recovery plan. The guidance is attractive, but after a year of misses, investors will likely demand proof of margin stabilization in Q1/Q2 before buying the turnaround.
Key Themes
Gross Profit Collapse
The core economic engine sputtered in Q4. Gross Profit fell 21% YoY to $172M, despite Revenue rising 3%. This disconnect was driven by a surge in benefits costs (inpatient, outpatient, pharmacy). Gross margin compressed to ~10.3% (derived), significantly below historical norms. Until this line item stabilizes, the bottom line is unsafe.
UnitedHealthcare Contract Reset
Management has renegotiated its master contract with UnitedHealthcare through 2028. Key change: pooling level for large claims drops to $500,000 starting Jan 1, 2026. This caps Insperity's exposure to catastrophic claims, which were a primary driver of the 2025 margin erosion. This is the single biggest factor underpinning the FY26 guidance.
Anemic Unit Growth
Paid Worksite Employees (WSEEs) grew just 1% YoY to 312,377. Growth has been decelerating/stagnant for four quarters. While the focus is on profitability, the lack of volume growth limits operating leverage. Guidance for Q1 2026 implies a contraction (-1.0% YoY) before recovering, suggesting the focus on repricing is dampening new sales or retention.
Cost Discipline
Operating expenses decreased 6% YoY in Q4 and 3% for the full year 2025. This includes absorbing significant implementation costs for the Workday partnership ($48M in 2025). Management is effectively controlling what they can (Opex) while struggling with what they can't (Medical Costs). This discipline provides a springboard for margin expansion if gross profits recover.
Q1 2026 Transition Pain
Despite the positive FY26 outlook, Q1 2026 guidance remains weak. Adjusted EPS is guided down 34% YoY ($1.03 vs $1.57 in 25Q1) and EBITDA down 21%. The recovery is back-weighted, meaning the first half of 2026 will likely still show negative comparisons before the strategic changes fully materialize in the financials.
Other KPIs
Reversing. Swung from a profit of $0.05 in 24Q4 to a significant loss. This missed consensus expectations and reflects the peak intensity of the benefits cost headwind.
Decelerating. Cash generation has been pressured by lower earnings. Adjusted cash sits at $57M, down from $134M a year ago. The company reduced buyback activity significantly in Q4 to preserve liquidity.
Stable. Up 1% YoY. While positive, this low-growth rate indicates the company is struggling to expand its user base in a meaningful way amidst pricing actions.
Guidance
Accelerating. Implies growth of 64% to 164% vs FY25 ($1.03). This is the 'light at the end of the tunnel' narrative. It relies on the successful execution of the UHC contract changes and pricing retention.
Accelerating. Represents a 30% to 76% increase over FY25 ($131M). The midpoint ($200M) is still below FY24 levels ($270M), indicating a recovery but not a full return to peak profitability.
Decelerating. Down 34% from $1.57 in 25Q1. This confirms that the turnaround will not be visible in the Q1 YoY comparisons, likely due to tough comps and the timing of cost resets.
Stable/Decelerating. The range (-1.5% to +1.5%) suggests the company is willing to sacrifice volume growth to fix margins. This is a crucial pivot from a 'growth' narrative to a 'margin repair' narrative.
Key Questions
Pricing Elasticity
With WSEE growth guided flat-to-down for FY26, are you seeing higher churn in the cohorts receiving the steepest price increases to cover the healthcare cost inflation?
Workday Revenue Contribution
You mention the HRScale rollout as a key driver. How much of the FY26 EBITDA recovery is predicated on new Workday sales versus simply fixing the legacy PEO margins?
Q1 vs FY Disconnect
Q1 EPS is guided down 34%, yet full year is guided up 100%+. What is the specific mechanism (seasonality, specific contract timing) that drives such a massive back-half acceleration?